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Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine
in Malawi
Sundos Khan a, Matthew Parrilloa, Andres H. Gutierrez b, Frances E. Terry b, Leonard Moise a,b,
William D. Martin b, and Anne S. De Groot a,b
aInstitute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Providence, RI, USA; bEpiVax, Inc.,
Providence, RI, USA
ABSTRACT
The RTS,S/AS01 malaria vaccine will undergo a pilot vaccination study in sub-Saharan Africa beginning in
2019. RTS,S/AS01 Phase III trials reported an efficacy of 28.3% (children 5–17 months) and 18.3% (infants
6–12 weeks), with substantial variability across study sites. We postulated that the relatively low efficacy of
the RTS,S vaccine and variability across sites may be due to lack of T-cell epitopes in the vaccine antigen,
and due to the HLA distribution of the vaccinated population, and/or due to ‘immune camouflage’, an
immune escape mechanism. To examine these hypotheses, we used immunoinformatics tools to compare
T helper epitopes contained in RTS,S vaccine antigens with Plasmodium falciparum circumsporozoite
protein (CSP) variants isolated from infected individuals in Malawi. The prevalence of epitopes restricted
by specific HLA-DRB1 alleles was inversely associated with prevalence of the HLA-DRB1 allele in the Malawi
study population, suggesting immune escape. In addition, T-cell epitopes in the CSP of strains circulating
in Malawi were more often restricted by low-frequency HLA-DRB1 alleles in the population. Furthermore,
T-cell epitopes that were highly conserved across CSP variants in Malawi possessed TCR-facing residues
that were highly conserved in the human proteome, potentially reducing T-cell help through tolerance.
The CSP component of the RTS,S vaccine also exhibited a low degree of T-cell epitope relatedness to
circulating variants. These results suggest that RTS,S vaccine efficacy may be impacted by low T-cell
epitope content, reduced presentation of T-cell epitopes by prevalent HLA-DRB1, high potential for
human-cross-reactivity, and limited conservation with the CSP of circulating malaria strains.
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Malaria is a disease that affects nearly half of the world’s
population, with the majority of deaths occurring in children
under the age of five.1 It is caused by the protozoan parasites
of the genus Plasmodium, of which four species infect
humans. Plasmodium falciparum is the species responsible
for the most severe form of malaria in humans and the high-
est rate of childhood mortality.2 Naturally acquired immunity
to malaria is slow to develop, is only moderately protective
and repeated infections with malaria appear to be required to
maintain immunity. Although protective immunogenic anti-
gens have been difficult to identify, both antibody-mediated
immunity and cell-mediated immunity to sporozoite stage
proteins have been demonstrated to play a critical role in
the host’s defense against malaria.3,4
Great effort has been dedicated to development of an
effective vaccine that can aid in the elimination of malaria.4
A number of approaches have been taken to target the
Plasmodium sporozoite stage, during which the parasite
invades hepatocytes and expands prior to invading
erythrocytes.5 Evidence for the feasibility of this approach
comes from studies demonstrating that irradiated
Plasmodium sporozoites confer protective immunity in
humans during subsequent sporozoite challenges.6 Despite
this success, challenges including the vaccine’s production
and route of administration have impeded mass vaccination
in endemic areas.4,7 Circumsporozoite protein (CSP), the
major surface antigen of the sporozoite, is one of the most
greatly studied malaria vaccine candidate antigens and has
been recognized to elicit both antibodies and T-cell
responses.8,9 The most advanced CSP vaccine, RTS,S, was
approved by the European Medicines Agency (EMA) to be
used in African children.10 This vaccine contains the last 19
NANP repeats of the central repeat region of CSP including
the C-terminal region, without the GPI anchor, from the
P. falciparum strain 3D7, fused to Hepatitis B surface antigen
(HBsAg). The fusion protein is co-formulated with free
HBsAg, which spontaneously assembles into a virus-like-par-
ticle. The licensed vaccine is formulated with the
GlaxoSmithKline AS01 adjuvant, which contains a mixture
of liposomes, and adjuvants Monophosphoryl lipid A (MPL)
and QS21.11 Correlates of immunity associated with the RTS,
S/AS01 vaccine have not been fully determined, although
vaccination has been shown to induce high titers of IgG
antibodies directed against the CSP’s central repeat region in
protected individuals and moderate levels of CD4+Th1
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responses specific to the CSP C-terminal region.12 The sig-
nificance of these immune responses is supported by studies
showing that CSP-specific CD4+ T-cells play an essential role
in protection against Plasmodium infection through the
induction of both humoral and cellular immune responses.
CD4+ cells may act as direct effectors through the release of
cytokines such as interleukin-2 (IL-2), tumor necrosis factor-α
(TNF-α), and interferon-γ (IFN-γ), or indirectly by assisting
antibody production and circulation.13–15
The RTS,S malaria vaccine is expected to begin pilot testing in
2019 in Ghana, Kenya, and Malawi in a World Health
Organization (WHO)-coordinated program to assess routine use
safety and impact on mortality in children ages 5 to 17 months.16
In multiple clinical trials, the vaccine showed partial protection in
adults, children, and infants, while also demonstrating significant
variation in efficacy against clinical malaria (12.5–86%).17–25
Pivotal phase 3 trials conducted in seven sub-Saharan countries
showed variable vaccine efficacy across 11 sites (40–77%).26
Variation has been attributed to factors including age differences,
adjuvant formulation, presence of maternal antibodies, interfer-
ence by co-administered vaccines, immune system maturity, and
immunological history.26,27Wehypothesize that antigen presenta-
tion-related issues involving host, pathogen and vaccine genetic
and immunological properties may have contributed to variability
inRTS,S efficacy. In this study, using immunoinformaticmethods,
we profiled the human class II MHC epitope landscape of RTS,S
and the corresponding sequences in circulatingCSP in aMalawian
cohort (published by Bailey et al. in 2012)28 to assess the potential
for the vaccine to prime CD4+ T-cells that are needed to generate
protective antibodies. We found low T-cell epitope content in the
73 amino acids representing the Th2 and Th3 regions of the CSP
sequence of RTS,S, reduced association of T-cell epitopes present
in this region with prevalent HLA-DRB1 in this malaria-endemic
region, poor vaccine coverage (in terms of conserved epitopes)
when comparing this region directly to the same sequence in
circulating CSP variants, a high degree of cross-conservation
between CSP T-cell epitopes (in the vaccine and circulating
strains) and the human proteome, and limited vaccine epitope
conservation with CSP epitopes in circulating malaria strains.
Each of these observations on its own, and when taken altogether,
may contribute to variable and suboptimal RTS,S efficacy.
Results
Imbalance in immunogenic potential of RTS,S vaccine
components
We have developed a method for evaluating the potential immu-
nogenicity of vaccine antigens, which involves estimating HLA
class II epitope content per unit length.29 We applied this method
to assess the T-cell epitope-related immunogenicity contained in
the vaccine sequence and the Hepatitis B surface protein. The
overall scores of these sequences were derived by summing the
number of sequences containing top 5% EpiMatrix Z-scores
(indicating moderate to high probability of HLA binding) for 9
HLA-DRB1 supertype alleles and normalizing for protein length
(number of 9-mer ‘hits’ per 1,000 9-mer assessments). In Figure 1,
the normalized EpiMatrix scores of the RTS,S vaccine antigens
(the truncated CSP and the HBV antigen, in terms of putative
class II epitopes per unit length) are plotted on the EpiMatrix
protein immunogenicity scale, where a random protein sequence
is expected to have a score of zero. Proteins scoring +20 are
considered to be potentially immunogenic.29 By comparison to
other well-known vaccine antigens, the CSP sequence from amino
acid 207 to amino acid 395 of P. falciparum strain NF54 in the
RTS,S vaccine, registered a low EpiMatrix Score of −29.15, reflect-
ing the low T-cell epitope density of this sequence. In contrast, the
Hepatitis B surface protein used in the vaccine registered an
EpiMatrix Score of +77.10, indicating that this antigen has
a higher density of predicted class II epitopes overall than CSP
(Figure 1). At a higher level of detail, Class II epitope predictions
are shown in Figure 2, where the core 9-mers of epitopes are
shaded degrees of blue based on their predicted binding like-
lihood. Notably, the NANP repeat region of CSP, which is
known to be a major antibody target,12 has no predicted class II
epitope content (Figure 2(a)). High T-cell epitope content is
observed in the Th2R and Th3R regions, which are known to be
highly variable, and some epitope content is also observed in the
conserved CD4+ T-cell epitope region (CS.T3). These observa-
tions are confirmed in prior studies that demonstrated CD4+
T-cell activity against the domains present in the C-terminal
region of the CSP.30 Thus, as has been confirmed by many other
laboratories, malaria-specific T-cell immunogenicity potential in
RTS,S is focused in the C-terminal region of the CSP component.
In contrast, the Hepatitis B surface antigen is rich in epitope
content spanning all common HLA class II alleles (Figure 2(b)).
Considering the fusion protein contained in RTS,S, which is made
up of truncated CSP linked to HBsAg, HBsAg T helper epitopes
outnumber CSP T helper epitopes in the fusion protein, 2.5 to 1
(181 epitopes in HBsAg to 73 in the truncated CSP). Given
a stoichiometry of non-linked HBsAg to fusion protein of 3:1,31
the proportion of HBsAg T cell epitopes to CSP T cell epitopes in
the vaccine is 9.9:1.
Inverse relationship between TH2R/TH3R T-cell
immunogenicity potential and HLA allele frequency in
Malawi
The immunogenicity potential of the malaria-specific compo-
nent of the vaccine was further characterized by comparing its
epitopes with epitopes found in the 73 amino acids represent-
ing the Th2 and Th3 regions of CSP that were sequenced from
individuals living in a malaria endemic area (Malawi, Bailey
et al. 2012). We compared the Th2 and Th3 regions of the
vaccine to the amino acid sequences of 57 unique
P. falciparum CSP variants obtained from Bailey et al.28
Overall, the Malawian CSP variant sequences displayed
a broad range of EpiMatrix HLA DR scores, from −47.21 to
1.12. Of all the CSP variants, only 33.3% (19 variants) scored
above 0, and none of these surpassed the threshold of 20
considered to reflect the minimal score for immunogenic
sequences of this length. The remaining 66.7% (38 variants)
exhibited even lower immunogenicity scores. The vaccine
strain (pUID8) sequence scored −8.26 on the immunogenicity
scale.
We found an inverse correlation between HLA DR allele
prevalence in the population and overall scores for the CSP
sequences found in the same population. Allele-specific
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EpiMatrix scores were defined for the vaccine and for the CSP
of circulating strains, and compared to the distribution of
HLA-DRB1 alleles reported for this study population.28
Across the CSP variant sequences, putative epitopes within
the top 5% of binders were more often restricted by HLA
DRB1*0801, DRB1*0401, and DRB1* 0701, all of which are
present in less than 20% of the study population (reflected by
the red shaded areas in Table 1). Interestingly, T-cell epitopes
were less prevalent in the CSP sequences for the HLA
DRB1*1501 and DRB1*0301 alleles, which are each present
in more than 25% of the study population (reflected by the
blue shaded columns in the epitope prevalence heat map
shown in Table 1).
CSP T cell epitopes were also predicted to bind with low
affinity to prevalent HLA DR alleles. Z-scores are roughly corre-
lated with T-cell epitope affinity for HLA binding. On an allele-
by-allele basis, the highest average Z-scores were associated with
DRB1*0401 and DRB1*0801, which were present in only 5.1%
and 8.5% of the study population, respectively. Conversely, the
lowest average Z-scores for the CSP Th2R-Th3R variants were
associated with DRB1*1301, DRB1*1501, and DRB1*0301, found
in 24.8%, 30.8% and 25.6% of the study population, respectively.
The HBsAg sequence had high average Z-scores associated with
DRB1*0401, DRB1*1101, DRB1*0701, DRB1*0101, DRB1*1501,
DRB1*0901, and DRB1*1301, a pattern that was not associated
with either common or rare alleles found within the study popu-
lation. The lowest average Z-scores of the HBsAg sequence were
associated with DRB1*0801 and DRB1*0301 (one low and one
high prevalence allele), thus immune escape does not seem to
occur in the case of HBsAg. The genetically fused CSP andHBsAg
sequence present in the RTS,S vaccine displayed an allele associa-
tion similar to that of the HBsAg alone (Table 2).
To determine whether the epitope content across the 57 CSP
variant sequences was significantly different from random
expectation, we performed an unpaired t-test to compare CSP
variant epitope content per allele, to the scores for a set of 1,000
random peptides of equal length. As expected, the Z-scores for
the set of random proteins passed the D’Agostino-Pearson
normality test with a zero mean and a standard deviation of
one. Based on their Z-scores, the total putative T helper epitope
content restricted by the high prevalence HLA allele families
DRB1*0101, DRB1*0301, DRB1*0701, DRB1*0901, DRB1*1301,
and DRB1*1501 was significantly skewed below zero for the 57
CSP Th2R/Th3R variants when compared to the scores of the
set of random peptides of equal length (p < 0.0001). This was
also true for epitopes restricted by DRB1*1101 (p = 0.0074).
Additionally, the mean values of the Z-scores of these alleles
demonstrated a significant shift to the left (lower average
Figure 1. Relative CD4+ T-cell immunogenicity potential of RTS,S vaccine components. This scale provides a normalized assessment of the potential
immunogenicity of the P. falciparum circumsporozoite protein (CSP) region (189 aa) and Hepatitis B surface antigen (226 aa) included in the RTS,S vaccine based
on the HLA class II epitope content. EpiMatrix scores are normalized and plotted on a standardized scale. The average score of a random protein sequence is
expected to be zero. EpiMatrix protein scores above zero have a higher potential for immunogenicity whereas scores below zero have a lower potential for
immunogenicity. On the left side of the scale are well known antigens that are included in other vaccines and other reference proteins, for comparison. The
P. falciparum CSP protein sequence scored low at −29.15. In contrast, Hepatitis B surface antigen scored 77.10, near the top of the immunogenicity scale.
216 S. KHAN ET AL.
Z-scores) as compared to observed distribution of the random
protein sequences of the same length. Scores for the remaining
(low prevalence) alleles (DRB1*0401 and DRB1*0801) were not
significantly different from random (p = 0.7953 and 0.9654,
respectively). In contrast, for tetanus toxin (used here to provide
an example of a strong antigen), the mean value of the Z-scores
for all the HLA DRB1 alleles exhibited a shift to the right when
compared to the set of random peptides, indicating higher
average Z-scores, which is expected for a highly immunogenic
antigen (Figure 3). These observations suggest that T-cell epi-
topes restricted by common HLA-DRB1 alleles in malaria-ende-
mic populations may be less common in the CSP variant
sequences than epitopes restricted by rare alleles. This finding
is unique to CSP and is not observed for tetanus toxin nor for a
set of random peptides of equal length.
Direct relationship between frequency of TH2R/TH3R
TCR-face patterns and immunosuppressive potential
To characterize the TCR-face conservation of the vaccine and
the 57 Malawian CSP strain variants, we performed two types of
JanusMatrix analyses. First, the predicted T-cell epitopes among
the 57 CSP variants and the vaccine (represented by pUID8 in
the dataset) were evaluated for conservation at the TCR face with
HLA-DRB1-restricted epitopes contained in the entire dataset of
57 CSP sequence variants (we use the word “JanusMalaria” to
describe this analysis). Second, the TCR-facing residues of CSP
variant epitopes were screened against HLA-DRB1-restricted
T-cell epitopes in the human proteome (“JanusHuman”) as
previously described.32
Two types of homology scores were calculated (Table 3).
The JanusMalaria homology score represents the degree of
conservation of a given sequence to epitopes contained in
circulating CSP C-terminal regions of P. falciparum strains
in Malawi. Accordingly, the hypothetical maximum possible
JanusMalaria score of a given peptide would be 57 (conserved
with all the strains), if every EpiMatrix predicted epitope
contained in the test sequence has a TCR-matching counter-
part in every variant in the dataset. None of the CSP variants
were highly conserved based on their JanusMalaria scores: the
range across all variants was 6.42 to 18.92, confirming pre-
vious reports of the high degree of variability of Th2R/Th3R
epitopes in circulating malaria strains.33
T-cell epitopes contained in the CSP Th2R/Th3R region were
also evaluated for conservation with the human proteome. In
previous studies, we found that epitopes that have high homol-
ogy with the human proteome may be tolerated or actively
regulatory (Treg) epitopes.34,35 The JanusHuman homology
score quantifies the degree to which putative T-cell epitopes
contained in the CSP variant sequences are cross-conserved
with sequences in the human proteome. Scores >2 indicate
epitopes that are conserved with the human proteome, and
potentially tolerogenic. The JanusHuman scores of the 57 CSP
variant strains ranged from 0.64 to 3.92. Of the CSP variants,
only 25% (14 variants) had a JanusHuman score below the
threshold value of 2 (reflecting elevated potential for immuno-
genicity). The remaining 75% (43 variants) scored 2 and above
(reflecting elevated potential for tolerance due to higher conser-
vation with the human proteome). We note that the vaccine
strain registered a JanusHuman score of exactly two.
To evaluate the relationship between the level of cross-
reactivity with human and the degree of strain conservation
within the population, we evaluated the relationship between
JanusHuman scores and the JanusMalaria scores.
Figure 2. MHC class II T-cell epitope content of the RTS,S vaccine components. (a) P. falciparum circumsporozoite protein (CSP) region (UniProt Q7K740) and (b)
Hepatitis B surface antigen (UniProt Q4KZP3) were parsed into overlapping 9-mer frames (columns) assessed for binding against a panel of nine class II HLA-DRB1
alleles (rows). Predicted binding potential to a given allele was determined and expressed as a Z-score; 9-mers with Z-scores above 1.28 represent the top 10% of
predicted binders and are shown in light blue, 9-mers with Z-scores above 1.64 represent the top 5% shown in medium blue and peptides with Z-scores above 2.32
are in the top 1% shown in dark blue. Frames with four or more hits (first row) are highlighted in yellow (EpiBars). Predicted putative class II T-cell epitopes for the
CSP region are clustered in the highly variable CD4+ T-cell region (Th2R). In contrast, the immunodominant B-cell epitope NANP repeat region does not contain any
predicted HLA-DR binding, indicated by the visibly clear space in the region analysis.
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JanusHuman scores of each variant were positively correlated
with both their EpiMatrix Cluster scores (R = 0.65) and their
JanusMalaria scores (R = 0.65; Figure 4). The more conserved
the T-cell epitopes are across the Malawian CSP variant
strains, the more their TCR-facing residues were cross-con-
served with the human proteome. Thus, epitopes that are
more conserved across circulating malaria strains in Malawi
were more human-like. Higher scoring T-cell epitope clusters
in the CSP sequences are also more human-like.
Overall T-cell epitope content of RTS,S TH2R/TH3R
relative to Malawian CSP is limited
The vaccine strain (pUID8; 11.21, highlighted in orange in
Figure 4) had a low JanusMalaria homology score, indicating
that the TCR-facing sequences of epitopes contained in the
vaccine were not highly conserved with their counterparts in
other Malawian CSP sequences. To quantitate the relatedness
of the T-cell epitope content between the CSP sequence of the
vaccine and the circulating strains, we performed an epitope
content comparison using the EpiCC algorithm.36 EpiCC
scores were calculated for pairwise comparisons of T helper
epitopes contained in the RTS,S vaccine with the homologous
epitope found in circulating strains (Table 4). The greater the
similarity of the T-cell epitope content between the reference
and query strains, the greater the EpiCC score. The maximum
EpiCC score for a sequence (baseline EpiCC score) reflects its
overall T-cell epitope content and is defined by comparing the
sequence against itself. The baseline EpiCC score of the vac-
cine was 0.0487. Nineteen of the 57 CSP variants had greater
T-cell epitope content (baseline EpiCC scores) than the
vaccine.
The Bailey et al. 201228 publication provided details on
the prevalence of 57 unique circulating CSP variants based
on the Th2 and Th3 region. Only three of the most pre-
valent CSP variants (pUID4, pUID12 and pUID8), includ-
ing the vaccine strain, had EpiCC scores that were more
than 40% of the variant’s baseline score (Table 4 and Figure
5). In addition, only one variant (pUID34), which was
found in only one sample, had an EpiCC score that repre-
sented more than 80% of the variant’s baseline EpiCC
score. Overall, the vaccine covered only 34.1% of the
T-cell epitope content found in CSP variants. This result
Figure 3. T-cell epitope score distribution of the 57 Malawian CSP variants per HLA-DR1 allele. Each graph represents the relative frequency distribution of the
EpiMatrix scores of the parsed 9-mers per HLA-DR1 allele for three data sets: The set of CSP variants (red), a set of random proteins (blue) and tetanus toxin (black).
Difference in the epitope content of the CSP variants and the set of random proteins was established by performing a t-test. Seven HLA-DRB1 alleles showed
significant difference from random proteins (p < 0.05), exhibiting a shift to the left from the normally distributed set of proteins (a,b,d,f,g,h,i). The remaining two
alleles (c,e) show no significant difference (p > 0.05).
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Table 1. Heat map representing the HLA-DR restricted immunological potential of the 57 CSP Malawi variants on an allele-by-allele level.


















pUID1 9.86  -0.11 -3.3 2.76 1.91 2.67 -0.17 3.17 -0.43 -0.72 
pUID2 -26.68  -1 -5.39 0.63 -1.68 -1.2 -0.48 -2.76 -0.8 -2.92 
pUID3 -27.03  -1 -5.39 0.63 -1.68 -1.3 -0.48 -2.76 -0.89 -2.92 
pUID4 2.94  -0.76 -3.3 1.29 1.82 3.05 -0.5 2.97 -0.58 -2.26 
pUID5 -38.8  -3.1 -3.64 -1.19 -2.35 0.7 -2.66 -2.74 -2.95 -4.77 
pUID6 -8.19  -2.73 -1.5 -1.03 1.24 1.07 -0.09 -0.5 1.15 -2.4 
pUID7 -8.53  -2.73 -1.5 -1.03 1.24 0.97 -0.09 -0.5 1.06 -2.4 
pUID8 -8.26  -2.81 -5.21 0.91 3.11 1.04 -0.81 0.73 -0.89 -0.89 
pUID9 -8.53  -2.73 -1.5 -1.03 1.24 0.97 -0.09 -0.5 1.06 -2.4 
pUID10 -2.7  -0.27 -4.9 1.34 1.73 2.58 -0.75 1.71 -0.81 -2.21 
pUID12 -22.89  -3.1 -3.64 -1.19 -0.57 2.85 -2.66 -1.1 -1.06 -2.91 
pUID13 -2.19  -0.27 -4.9 1.34 1.73 2.68 -0.75 1.81 -0.71 -2.21 
pUID14 -9.2  -4.53 -0.84 -0.85 1.09 5.07 -0.42 0.12 -0.52 -4.5 
pUID15 0.46  -0.27 -4.9 1.34 1.73 4.43 -0.75 1.71 -0.81 -2.21 
pUID16 -4.1  -0.76 -3.3 1.29 1.82 2.67 -0.5 1.22 -2.57 -2.26 
pUID17 -13.74  -2.7 -3.33 0.78 1.29 1.11 -0.75 -0.88 -0.85 -2.7 
pUID18 12  -0.76 -1.38 1.29 1.82 4.75 -0.5 2.87 -0.69 -0.36 
pUID19 -5.42  -4.49 -0.63 0.77 1.04 3.51 -0.36 0.04 1.43 -4.46 
pUID20 -47.21  -3.01 -5.34 -1.54 -2.37 -1.22 -2.59 -3.11 -3.31 -5.12 
pUID21 -18.12  -4.7 -0.94 0.56 -1.07 1.67 -2.31 -0.28 1.13 -4.66 
pUID22 18.12  -1.97 1.04 1.08 1.66 6.52 0.22 0.83 2.99 -1.78 
pUID23 -26.05  -3.1 -3.64 -1.19 -0.57 1 -2.66 -1.1 -1.06 -2.91 
pUID24 -5.37  -2.73 -1.5 -1.03 1.24 2.82 -0.09 -0.5 1.06 -2.4 
pUID25 -13.78  -2.7 -3.33 0.78 1.29 1.1 -0.75 -0.88 -0.85 -2.7 
pUID26 -28.09  -2.39 -3.52 -1.15 -0.4 -1.11 -0.8 -1.07 -1.24 -4.76 
pUID27 -30.19  -3.02 -2.75 0.21 -2.84 0.15 -2.23 -0.73 -1.42 -5.02 
pUID28 -27.95  -1 -5.39 0.63 -1.68 -1.58 -0.48 -2.76 -1.16 -2.92 
pUID29 16.1  -1.63 0.97 -0.73 0.51 6.7 -0.6 0.7 3.67 -0.17 
pUID30 -26.68  -1 -5.39 0.63 -1.68 -1.2 -0.48 -2.76 -0.8 -2.92 
pUID31 0.34  -2.36 -3.28 1.35 1.84 3 -0.48 2.93 -0.59 -2.21 
pUID32 -26.05  -3.1 -3.64 -1.19 -0.57 1 -2.66 -1.1 -1.06 -2.91 
pUID33 6.87  -0.27 -2.99 1.34 1.73 4.38 -0.75 1.7 -0.81 -0.31 
pUID34 -15.06  -2.81 -5.21 0.91 1.34 0.84 -0.81 -0.92 -1.08 -1.07 
pUID35 14.26  -0.11 -3.3 2.76 1.91 4.68 -0.17 3.36 -0.24 -0.54 
pUID36 0.97  -0.27 -4.9 1.34 1.73 4.53 -0.75 1.81 -0.71 -2.21 
pUID37 -13.23  -2.7 -3.33 0.78 1.29 1.21 -0.75 -0.78 -0.75 -2.7 
pUID38 -2.36  -4.49 -0.63 0.77 1.04 5.28 -0.36 0.04 1.44 -4.46 
pUID39 -22.96  -3.1 -3.64 -1.19 -0.57 2.81 -2.66 -1.1 -1.06 -2.91 
pUID41 14.26  -0.11 -3.3 2.76 1.91 4.68 -0.17 3.36 -0.24 -0.54 
pUID43 -16.21  -2.59 -5.12 1.13 1.56 0.51 -0.72 1.19 -2.69 -2.74 
pUID44 -26.68  -1 -5.39 0.63 -1.68 -1.2 -0.48 -2.76 -0.8 -2.92 
pUID45 -26.05  -3.1 -3.64 -1.19 -0.57 1 -2.66 -1.1 -1.06 -2.91 
pUID46 6.1  -0.76 -3.3 1.29 1.82 4.9 -0.5 2.97 -0.58 -2.26 
pUID48 12  -0.76 -1.38 1.29 1.82 4.75 -0.5 2.87 -0.69 -0.36 
pUID49 -8.74  -4.49 -0.63 0.77 1.04 3.24 -0.36 0.04 -0.24 -4.46 
pUID50 -20.29  -2.7 -3.33 0.78 1.29 0.83 -0.75 -2.53 -2.74 -2.7 
pUID51 0.46  -0.27 -4.9 1.34 1.73 4.43 -0.75 1.71 -0.81 -2.21 
pUID52 -26.05  -3.1 -3.64 -1.19 -0.57 1 -2.66 -1.1 -1.06 -2.91 
pUID53 6.1  -0.76 -3.3 1.29 1.82 4.9 -0.5 2.97 -0.58 -2.26 
pUID54 -27.03  -1 -5.39 0.63 -1.68 -1.3 -0.48 -2.76 -0.89 -2.92 
pUID55 0.34  -2.36 -3.28 1.35 1.84 3 -0.48 2.93 -0.59 -2.21 
pUID56 9.86  -0.11 -3.3 2.76 1.91 2.67 -0.17 3.17 -0.43 -0.72 
pUID57 -13.74  -2.7 -3.33 0.78 1.29 1.11 -0.75 -0.88 -0.85 -2.7 
pUID59 -4.1  -0.76 -3.3 1.29 1.82 2.67 -0.5 1.22 -2.57 -2.26 
pUID60 3.5  -2.36 -3.28 1.35 1.84 4.85 -0.48 2.93 -0.59 -2.21 
pUID61 3.5  -2.36 -3.28 1.35 1.84 4.85 -0.48 2.93 -0.59 -2.21 
pUID62 -32.85  -3.1 -3.64 -1.19 -2.35 0.8 -2.66 -2.74 -1.25 -3.1 
% study population  
with allele: 11.1% 25.6% 5.1% 17.1% 8.5% 6.84% 34.2% 24.8% 30.8% 
For each Malawian CSP variant, epitope mapping (for the entire CSP variant sequence) was performed separately for each of the nine supertype HLA-DR alleles. The
overall protein score for each allele is color-coded (blue for low epitope content, red for high epitope content). The prevalence of epitope hits per allele is clear in
the heat map Few sequences had epitopes that were restricted by HLA DRB1*1301, DRB1*1501, and DRB1*0301, which are common HLA alleles in the Malawian
population. More EpiMatrix hits were identified HLA DRB1*0801 and DRB1*0401, which rare HLA alleles, not often found in the Malawi population.
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showed that the T-cell epitope content shared between the
vaccine and the Malawian CSP variants is very limited. The
EpiCC score has been used to define a threshold for vaccine
efficacy in influenza studies;36 a threshold for malaria vac-
cines has not been defined.
The average EpiCC score of the vaccine compared to all the
variants was 0.0159. Thirty-four CSP variants (out of 57) had
average EpiCC scores higher than that of the vaccine, i.e. there
were 34 variants that, on average, share more T-cell epitope
content with Malawian variants than the vaccine strain.
Based on these results, the vaccine strain, due to T-cell
epitope content, may be a less than optimal selection for
a vaccine candidate for use in Malawi. Given the set of CSP
sequences circulating in Lilongwe, Malawi at the time of
sampling, the best vaccine strain to pick should have a high
intrinsic EpiCC score (high T helper epitope content) and
a low JanusHuman score (low potential for generating
tolerance). For example, pUID1 has a slightly higher average
EpiCC score (0.017) than the vaccine’s pUID8 (0.016), and
also has a JanusHuman Homology Score below 2 (1.91), while
the vaccine’s pUID8 strain Janus score is 2, and pUID1 was
the second most prevalent variant in Malawi (found 22 times).
We identified strains that share on average more T-cell epi-
topes with the CSP variants, but their JanusHuman Homology
scores were above 2 (e.g. pUID18, pUID46, pUID48, and
pUID53). Moreover, the average EpiCC scores of the CSP
variants directly correlated with JanusHuman Homology
scores (R = 0.79; p < 0.01). Hence, CSP variants that share
more T-cell epitope content have epitopes that are more
cross-conserved with human proteins and more likely to be
tolerated or actively regulatory. This result is consistent with
the correlation found between JanusHuman and JanusMalaria
homology scores. Finally, CSP variants with higher baseline
epitope content also had lower JanusMalaria scores





























DRB1*0401 6 5.1% 0.01 0.03 0.13 0.08 0.11
DRB1*0801 10 8.5% 0.01 0.02 -0.07 -0.02 0.15
DRB1*1101 40 34.2% -0.05 -0.02 0.11 0.05 0.12
DRB1*0701 20 17.1% -0.08 -0.07 0.31 0.12 0.17
DRB1*0101 13 11.1% -0.09 -0.08 0.09 0.01 0.10
DRB1*0301 32 27.4% -0.10 -0.07 -0.16 -0.12 0.10
DRB1*0901 8 6.8% -0.15 -0.11 0.22 0.06 0.11
DRB1*1301 30 25.6% -0.22 -0.18 0.02 -0.08 0.11
DRB1*1501 36 30.8% -0.23 -0.21 0.30 0.05 0.14
Other 31 26.5% N/A N/A N/A N/A N/A
*The five sets are sorted based on the average EpiMatrix Z-scores of the circulating CSP Malawian strains from the highest to the lowest scores. Higher Z-
scores are shown as red shaded areas and lower Z-scores are shown as blue shaded areas.
Figure 4. Cross-conservation of the 57 Malawi CSP variants with the human genome. JanusMatrix analysis of the predominant T-cell epitope clusters in each
CSP Malawian variant identified T-cell epitopes that are more likely to activate regulatory T-cells (cross-conservation with the human genome) and T-cell epitopes
that are conserved in the Malawian parasite population (cross-conservation with the CSP Malawi variants). (a) Each point represents JanusMatrix human scores
(JanusMatrix conservation in human genome) and JanusMalaria scores (JanusMatrix conservation in Malawi malaria strains) of a Malawian CSP variant. A correlation is
established: the more conserved the T-cell epitopes are across the Malawian CSP variant strains, the more their TCR-facing residues are cross-conserved with the
human genome. (b) Each point represents JanusMatrix human score and EpiMatrix cluster scores of a Malawian CSP variant. A correlation is also observed between
these value sets: higher EpiMatrix cluster scores are correlated with higher JanusMatrix human scores.
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(R = −0.33; p = 0.01), meaning that T cell immunogenicity
potential of circulating CSP and their epitope conservation are
inversely related.
Discussion
To prevent liver stage malaria infection, the RTS,S malaria
vaccine should exhibit a number of desired features that involve
CD4+ T-cell induction. First it should generate strong antibody
responses against sporozoites.37–40 CD4+ T-cells drive antibody
maturation and improve antibody affinity to support protective
antibody responses.41 Thus, the CD4+ T-cell response induced
by RTS,S and by CSP in the context of natural infection requires
further study. In addition, CD8+ T-cells require CD4+ T-cell
help in immunization to generate a strong primary response to
produce durable memory that is needed for effective recall upon
secondary challenge.42 Since CD8+ T-cell responses to sporo-
zoite proteins are also critical for protection against liver stage
infection38 and CD8+ T-cell responses induced by RTS,S may
contribute to infection control should parasites evade antibody
recognition, modulation of CD4+ T cell help may reduce
CD8+ T cell efficacy. Finally, the ideal CSP vaccine should be
effective across a broad spectrum of P. falciparum strains and
across the HLA diverse human population.
Despite initial optimism, the RTS,S vaccine has been
shown to have significant heterogeneity in the vaccine’s effi-
cacy among participants and across the clinical trial sites.
Factors contributing to the moderate efficacy of the RTS,S
vaccine include the participant’s age, immune history, co-
administration with other vaccines, dosing and the adjuvant
system.26,27 However, there are additional factors that can
impact immune responses. One factor is the restriction of
the CD4+ T-cell epitope content which may dampen immune
response. Although it is well known that the T-cell sequences
of CSP are variable, we also found that the concentration of
T cell epitope content of the CSP sequence found in circulat-
ing strains of malaria in Malawi was variable, with the major-
ity of the variants, including the 3D7 strain used in the RTS,S
Figure 5. EpiCC score of the RTS,S malaria CSP strain sequence against the 57 circulating Malawian CSP variants. EpiCC assesses the relatedness of T-cell
epitopes contained in the CSP sequence of the RTS,S vaccine and those in the Malawi CSP variant strains based on a comparison of their epitope sequences and
EpiMatrix binding scores. The higher the EpiCC score, the higher the T-cell epitope content, the more related the epitopes of two strains are and more potential of
cross-protection. On the radar plot, each axis represents one of the CSP malaria variants circulating in Malawi (number 1 = pUID1, 2 = pUID2, and so on). EpiCC
scores of the RTS,S vaccine strain (pUID8) compared to the CSP Malawian variants are shown in orange. EpiCC scores of an alternative candidate strain (pUID1)
compared to the CSP Malawian variants are shown in blue. pUID1 shares, on average, slightly more T cell epitope content with the circulating CSP variants compared
to the vaccine’s pUID8. Baseline EpiCC scores of each variant strain (comparison to self) are shown as open circles.
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pUID5 -38.8 18 6.14 20.54 0.64 10.43
pUID20 -47.21 2 1.47 15.62 1.08 6.42
pUID62 -32.85 1 0.01 21.24 1.25 9.81
pUID27 -30.19 1 1.18 25.58 1.35 7.35
pUID12 -22.89 13 3.81 25.22 1.61 9.94
pUID23 -26.05 2 0.84 25.22 1.61 9.94
pUID32 -26.05 2 0.37 25.22 1.61 9.94
pUID39 -22.96 2 0.16 25.22 1.61 9.94
pUID45 -26.05 1 0.07 25.22 1.61 9.94
pUID52 -26.05 1 0.01 25.22 1.61 9.94
pUID34 -15.06 1 0.27 33.29 1.77 11.23
pUID1 9.86 22 9.14 47.87 1.89 11.11
pUID56 9.86 1 0.02 47.87 1.89 11.11
pUID21 -18.12 3 1.02 29.87 1.95 7.32
pUID8 -8.26 11 4.71 37.27 2 11.21
pUID17 -13.74 2 2.86 32.42 2.24 11.1
pUID57 -13.74 1 0.02 32.42 2.24 11.1
pUID28 -27.95 1 0.75 25.75 2.28 15.11
pUID35 14.26 3 0.31 48.63 2.29 11.11
pUID41 14.26 2 0.14 48.63 2.29 11.11
pUID14 -9.2 3 2.41 39.5 2.32 6.86
pUID6 -8.19 10 5.27 37.31 2.35 12.83
pUID7 -8.53 9 6.26 37.11 2.35 12.91
pUID9 -8.53 10 4.1 37.11 2.35 12.91
pUID24 -5.37 5 0.82 37.11 2.35 12.91
pUID2 -26.68 14 8.61 26.5 2.39 15.44
pUID30 -26.68 1 0.6 26.5 2.39 15.44
pUID44 -26.68 2 0.1 26.5 2.39 15.44
pUID3 -27.03 25 11.68 26.3 2.39 15.56
pUID54 -27.03 1 0.01 26.3 2.39 15.56
pUID50 -20.29 1 0.03 31.38 2.47 12
pUID38 -2.36 1 0.14 39.08 2.57 11.09
pUID25 -13.78 2 0.88 32.4 2.62 11.19
pUID10 -2.7 4 4.26 40.52 2.63 13.75
pUID15 0.46 3 1.83 40.52 2.63 13.75
pUID51 0.46 1 0.06 40.52 2.63 13.75
pUID37 -13.23 1 0.16 32.72 2.67 11.48
pUID13 -2.19 4 2.74 40.82 2.79 13.63
pUID36 0.97 1 0.04 40.82 2.79 13.63
pUID49 -8.74 1 0.08 38.13 2.81 11.95
pUID43 -16.21 1 0.1 33.53 2.85 9.35
pUID19 -5.42 3 1.53 37.3 2.86 11.59
pUID29 16.1 1 0.58 49.67 2.96 8.19
pUID33 6.87 3 0.42 40.5 3.04 13.5
pUID22 18.12 4 1.15 50.85 3.21 9.93
pUID26 -28.09 2 1.33 25.67 3.28 14.61
pUID18 12 8 1.5 43.5 3.88 17.73
pUID48 12 1 0.07 43.5 3.88 17.73
pUID16 -4.1 2 1.8 42.48 3.88 18.92
pUID59 -4.1 1 0.02 42.48 3.88 18.92
pUID31 0.34 2 0.71 42.3 3.92 12.24
pUID55 0.34 2 0.03 42.3 3.92 12.24
pUID60 3.5 1 0.04 42.3 3.92 12.24
pUID61 3.5 1 0.01 42.3 3.92 12.24
pUID4 2.94 11 7.12 43.83 3.92 17.96
pUID46 6.1 1 0.1 43.83 3.92 17.96
pUID53 6.1 2 0.04 43.83 3.92 17.96
aAverage depth of coverage in the human genome for each EpiMatrix hit of a given CSP variant sequence. JanusHuman scores above two suggest
elevated potential for tolerance while scores below 2 suggest elevated immunogenic potential.
bAverage depth of coverage in the set of CSP variants for each EpiMatrix hit of a given CSP variant. JanusMalaria score represents the degree of
conservation of a CSP variant to epitopes contained in circulating CSP C-terminal regions of P. falciparum strains in Malawi.
Table is colored by column; high values are shown in red and low values in blue.
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Table 4. T-cell epitope content comparison (EpiCC) results.
Name









pUID1 22 0.0539 0.013 24.16 0.0171
pUID2 14 0.0377 0.013 34.54 0.0161
pUID3 25 0.0377 0.013 34.57 0.0162
pUID4 11 0.0508 0.021 41.43 0.0215
pUID5 18 0.0343 0.0131 38.18 0.0131
pUID6 10 0.0459 0.0097 21.04 0.0166
pUID7 9 0.0458 0.0097 21.06 0.0166
pUID8 11 0.0487 0.0487 100 0.0159
pUID9 10 0.0458 0.0097 21.06 0.0166
pUID10 4 0.0476 0.013 27.33 0.0176
pUID12 13 0.0423 0.0211 49.89 0.0145
pUID13 4 0.0477 0.013 27.3 0.0175
pUID14 3 0.0443 0.0178 40.2 0.0124
pUID15 3 0.0492 0.013 26.44 0.0181
pUID16 2 0.0475 0.021 44.28 0.0212
pUID17 2 0.0441 0.0081 18.37 0.0154
pUID18 8 0.0555 0.021 37.89 0.022
pUID19 3 0.0459 0.0096 21.02 0.0159
pUID20 2 0.0294 0.0114 38.89 0.0109
pUID21 3 0.0425 0.0195 45.8 0.0126
pUID22 4 0.0559 0.0097 17.28 0.0166
pUID23 2 0.0407 0.0211 51.85 0.014
pUID24 5 0.0474 0.0097 20.35 0.0171
pUID25 2 0.0441 0.0081 18.37 0.0154
pUID26 2 0.0376 0.013 34.66 0.0157
pUID27 1 0.0373 0.0162 43.25 0.0122
pUID28 1 0.0375 0.013 34.68 0.016
pUID29 1 0.0543 0.0081 14.9 0.015
pUID30 1 0.0377 0.013 34.54 0.0161
pUID31 2 0.0492 0.021 42.76 0.0169
pUID32 2 0.0407 0.0211 51.85 0.014
pUID33 3 0.0524 0.013 24.82 0.0181
pUID34 1 0.0455 0.0407 89.56 0.0153
pUID35 3 0.0556 0.013 23.41 0.0176
pUID36 1 0.0493 0.013 26.41 0.018
pUID37 1 0.0441 0.0081 18.34 0.0156
pUID38 1 0.0475 0.0096 20.32 0.0159
pUID39 2 0.0422 0.0211 49.89 0.0145
pUID41 2 0.0556 0.013 23.41 0.0176
pUID43 1 0.0441 0.021 47.58 0.0135
pUID44 2 0.0377 0.013 34.54 0.0161
pUID45 1 0.0407 0.0211 51.85 0.014
pUID46 1 0.0524 0.021 40.17 0.022
pUID48 1 0.0555 0.021 37.89 0.022
pUID49 1 0.0443 0.0096 21.79 0.0158
pUID50 1 0.0409 0.0081 19.8 0.0152
pUID51 1 0.0492 0.013 26.44 0.0181
pUID52 1 0.0407 0.0211 51.85 0.014
pUID53 2 0.0524 0.021 40.17 0.022
pUID54 1 0.0377 0.013 34.57 0.0162
pUID55 2 0.0492 0.021 42.76 0.0169
pUID56 1 0.0539 0.013 24.16 0.0171
pUID57 1 0.0441 0.0081 18.37 0.0154
pUID59 1 0.0475 0.021 44.28 0.0212
pUID60 1 0.0508 0.021 41.41 0.0174
pUID61 1 0.0508 0.021 41.41 0.0174
pUID62 1 0.0374 0.0131 34.98 0.0108
aOverall T cell epitope content of each variant. CSP variants with baseline EpiCC scores (comparison to self) greater than that of the vaccine (0.0487) are
shown in bold font.
bThe greater the similarity of the T-cell epitope content between the vaccine and query strains, the greater the EpiCC score.
cEpiCC score/variant baseline EpiCC score*100. Prevalent CSP variants (found 10 or more times) with the highest % of the variant baseline EpiCC score
are shown in bold font.
dCSP variants with average EpiCC scores greater than that of the vaccine (0.0159) are shown in bold font.
Table is colored by column; high values are shown in red and low values in blue.
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vaccine, scoring low for overall T-cell epitope content. Also,
the impact of HLA-DR restriction with respect to HLA pre-
valence in malaria endemic regions is worth noting. We found
that the HLA-DR restriction of T-cell epitopes contained in
the RTS,S vaccine (and many other CSP sequences found in
naturally circulating variants) was inversely correlated with
the prevalence of those epitopes of HLA-DR alleles in Malawi.
Furthermore, circulating P. falciparum strains in Malawi also
possess putative T-cell epitopes in Th2/Th3 that are restricted
by HLA-DRB1 alleles that are rare in the Malawi population.
This suggests that immune escape by P. falciparum may be
occurring at the population level, and that the parasite has
adapted to the local human population and evolved to escape
HLA-DR-restricted immune responses, a mechanism that is
exploited by several other pathogens.43–45
Our analysis therefore support studies that implied that T-cell
epitope escape may be driven by immune pressure46–49 in ende-
mic populations. The dearth of predicted HLA-DRB1 restricted
T-cell epitopes we find in the CSP-derived sequence of RTS,S,
together with the poor match to circulating strains, may not
support the T-cell help from memory T cells during vaccination
that may be needed to reduce disease burden. On the other hand,
substantial T-cell epitope content in the HBV surface antigenmay
counterbalance to provide the T-cell help that may be required for
induction of anti-CSP antibodies.
Evading the immune system is key to the survival of
P. falciparum. It is not surprising therefore that
P. falciparum strains in circulation also utilize immune
camouflage, an immune evasion strategy that our group first
described in 2013.32 Immune camouflage is exhibited by
pathogens that possess T-cell epitopes that have a high degree
of cross-conservation with the human proteome at TCR-
facing residues. Presentation of such epitopes on HLA may
induce regulatory T-cells that in turn suppress productive
effector CD4+ and CD8+ T-cell responses needed to generate
sustained levels of protective antibodies and block liver stage
infection. In this study, using the JanusMatrix algorithm, we
found that HLA-DRB1 restricted T-cell epitopes that are
highly conserved across Malawian CSP variants are likely to
cross-react with epitopes derived from the human proteome.
Several publications from our group have shown
a relationship between poorly performing vaccines and the
presence of such putative Treg inducing epitopes in HCV,50
HIV,50 and influenza A.35 While it is clear that immune
camouflage in circulating strains may have no relevance in
the context of a naive individual from a non-endemic region
who is vaccinated with RTS,S, the presence of malaria CS-
antigen-specific Tregs that have been induced by prior expo-
sure may dampen immune response to RTS,S in previously
exposed individuals. Taken together, the overall reduction in
T-cell epitope content and the presence of residual epitopes
that are cross-conserved with self and potentially tolerated
may explain the low levels of CSP specific CD4+ T-cells
observed in RTS,S clinical trials, and that vaccine’s moderate
efficacy.
Our analysis of circulating CSP sequences using the EpiCC
tool also suggest that careful selection of vaccine strains might
lead to improved efficacy, a vaccine strain with good T-cell
content and low Janus score was identified from the
circulating CSP strains in Malawi that would be a better fit
for the parasite population in Malawi than the strain present
in the RTS,S vaccine. An alternative would be to immune
engineer a more immunogenic and representative sequence.
An important caveat to our data interpretation is that the
degree of CSP sequence diversity may differ from one population
to another. Thus, the findings for the P. falciparum population in
Malawi may not represent findings for parasite populations in
other endemic areas. We have not examined the contributions of
CD8 T-cells in this study as the primary focus was on T-cell help
(and regulatory T-cells). The findings of this study would be
further supported by ex vivo immunological validation using
HLA-typed samples from trial participants and sites. Based on
data presented here, when designing a new Malaria vaccine, it
may be useful to include a comprehensive analysis of all vaccine
components such as: 1) CSP sequence isolates and HLA infor-
mation from other trial sites, 2) correlation of participant HLA
and in silico predictions with vaccine efficacy and titers induced
to CSP/HBsAg, 3) evaluation of vaccine potential to induce
regulatory vs. effector T-cell responses and to suppress B cell
responses based on CSP epitope humanness.
In conclusion, the deployment of the RTS,S malaria
vaccine may be impacted by challenges of low immuno-
genic content, poor coverage of pathogenic variants, and
the potential for human-cross-reactivity, all of which may
limit the development of an effective immune response. In
silico immunoinformatics tools offer powerful mechanisms
to select and refine the next generation of malaria vaccine
candidate antigens. They may also be applied using the
approach described here to understand clinical trial out-
comes for other vaccines.
Methods
Sequences
The complete amino acid sequence of the RTS,S vaccine was
found in the US20050002958A1 patent (Cohen et al. 2005).51
Beginning from the N-terminus of the CSP-HBsAg fusion, the
first 189 amino acids are derived from CSP (from the 3D7
strain of P. falciparum), followed by the fusion protein linker
sequence (GPVTN), and finally 226 amino acids derived from
Hepatitis B virus pre-S2 protein (adw serotype).
A set of 57 unique CSP variant sequences, each 73 amino
acids in length, identified within the falciparum parasite popula-
tion in Lilongwe, Malawi using massively parallel pyrosequen-
cing on the Plasmodium falciparum CSP Th2R and Th3R T-cell
epitope regions, have been used to represent the CSP variant
frequency of the Th2R region epitopes within the Malawi popu-
lation. Each variant was assigned a unique population identifier
(pUID) (GenBank JN634586-JN634642).28
For purposes of comparison with Malawian CSP variants,
we generated a set of 1,000 random proteins each 73 amino
acids long using the SWISSPROT random protein generator
at natural amino acid frequencies referenced in SWISSPROT.
Also for comparison to a well characterized vaccine antigen,
we obtained the sequence of tetanus toxin from Clostridium
tetani strain E88, (UniProt P04958).
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MHC binding potential analysis
The EpiMatrix T-cell epitope mapping algorithm was used to
identify putative class I and class II HLA binding epitopes within
a protein sequence.29 Because 9 amino acids are the minimal
length an HLA binding groove accepts, input sequences were
parsed into overlapping 9-mer frames in which each frame over-
laps the last by 8 amino acids. Each 9-mer was assessed for its
binding potential against a panel of nine class II HLA-DRB1
alleles, DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*0901, DRB1*1101, DRB1*1301, and
DRB1*1501, which are “supertype” alleles representative of
HLA class II of over 95% of the global population.52 Each
EpiMatrix peptide-to-allele assessment was normalized based
on the frequency of T-cell epitopes derived from a set of random
protein sequences to arrive at a Z-score. EpiMatrix Z-scores
above 1.64 were considered hits and represent the top 5% of
predicted binders. EpiMatrix Z-scores above 2.32 represent the
top 1%, even more likely to bind HLA alleles. An EpiMatrix
Protein Score was calculated to determine the overall epitope
content of an input sequence with respect to random expecta-
tion, where positive scores indicate an excess of putative epitopes
and negative scores indicate a lack of putative epitopes relative to
a random sequence of equivalent length. Regions of elevated
putative epitope density, called T-cell epitope “clusters” were
identified using ClustiMer, an algorithm that identifies
sequences that have a promiscuous HLA Class II binding
profile.29 The RTS,S vaccine sequence, the set of 57 CSP variant
sequences, the 1000 random protein reference set and the teta-
nus toxin sequence were analyzed using EpiMatrix and
ClustiMer, and compared for T-cell epitope content and/or for
cross-conservation as described below.
T-cell epitope content by HLA-DRB1 allele
57 Malawian Th2/Th3 CSP variants, each 73 amino acids in
length, generated a total of 3,705 9-mer frames. The Z-scores for
each 9-mer within each HLA-DRB1 allele were used to create
a histogram to evaluate the frequency distribution and generate
a mean for the CSP set per HLA-DRB1 allele. Analysis was
repeated for the set of 1,000 random protein sequences of the
same length, which generated 65,000 9-mer frames. Finally,
HLA-specific analysis was performed for the Tetanus Toxin
protein, 1,315 amino acids in lengths and comprising 1,307
9-mer frames. Smoothed histograms were generated to visualize
the mean difference between the datasets, per HLA-DRB1 allele.
Cross-conservation analysis
The JanusMatrix algorithm was used to predict potential cross-
reactivity on the basis of shared T-cell-receptor-interacting resi-
dues of putative T-cell epitopes found among the set of 57 unique
Th2/Th3 CSP variant sequences and within the human
proteome.32 JanusMatrix parsed the amino acid sequences of
EpiMatrix clusters into 9-mer frames and then designated TCR-
facing residues (positions 2,3,5,7, and 8) andMHC-binding amino
acid residues (positions 1, 4, 6, and 9). Next, JanusMatrix searched
specified databases (CSP variants and UniProt reviewed human
proteome) for 9-mers with identical TCR-facing residues
compared to the input sequence, provided they are predicted to
bind to the same HLA allele. Two peptides related in such a way
were considered “cross-conserved”. A JanusMatrix Homology
Score was calculated, representing the average depth of coverage
in the search database for eachEpiMatrix hit of the input sequence.
Based on a comparison with published epitopes in the immune
epitope database (IEDB, http://www.iedb.org/), peptides with
higher JanusMatrix Human Homology Scores (more human-
like) are more likely to induce the release of the cytokine IL-10
than IL-4. These two cytokines are more often associated with
a regulatory T-cell response and an effector T-cell response,
respectively. Conversely, peptides with lower JanusMatrix
Human Homology Scores (less human-like) are more likely to
induce the release of the effector cytokine IL-4.50,53 Accounting for
the fact that a certain degree of cross conservation is expected for
any putative ligand, a JanusMatrix Homology Score greater than
two calculated for human proteome was used as a threshold for
human cross-conservation. The threshold represents the top 5%of
scores for human sequences based on an analysis of large dataset of
putative ligands composed of random amino acids. Scores from
JanusMatrix analysis using the human proteome database are
referred to as JanusHuman and those from analysis of the variant
CSP sequence database as JanusMalaria. In this study, JanusMatrix
was used to analyze T-cell epitope clusters in each Malawian
variant CSP sequence to evaluate the potential of cross-reactivity
with two sequence databases – the human proteome
(JanusHuman) and the set of 57 Malawian variant CSP sequences
(JanusMalaria).
T-cell epitope content comparison (EpiCC)
The epitope content comparison algorithm (EpiCC) was
applied to determine the relatedness of the putative class
II T-cell epitopes shared between the vaccine and each CSP
variant.36 EpiCC evaluates the relatedness of T-cell epitopes
contained in the protein sequence of a vaccine and those
found in the protein sequence of a variant strain of the
same organism, by comparing their epitope sequences and
EpiMatrix binding scores. The maximum EpiCC score for
a vaccine was defined by comparing the T-cell epitopes
contained in the protein sequence to itself (baseline
EpiCC score). This score represents the epitope density of
the sequence and the binding probabilities (EpiMatrix
Z-scores) of its epitopes. When comparing a vaccine to
a variant, the EpiCC score would be equal to or lower
than the baseline scores of the vaccine and the variant.
A vaccine was considered to share more T-cell epitope
content with a variant when the EpiCC score was closer
to the variant’s baseline score.
To determine T-cell epitope relatedness, the baseline EpiCC
score of each variant Malawian sequence and the scores relating
variant sequences and the vaccine strain (pUID8) were calculated.
Each CSP variant was also compared to all other CSP variants and
an average EpiCC score was calculated for each of these compar-
isons to determine whether another variant strain might be
a better candidate for use as a vaccine in Malawi. Variants with
higher average EpiCC scores in this comparison would have more
shared T-cell epitope content with other circulating CSP variants.
The relationship between the baseline and average EpiCC scores of
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the vaccine and CSP variants and Janus scores were calculated to
determine whether the prevalence of a specific strain correlated
with the T-cell epitope content of the strain.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism version
6 and Microsoft Excel version 15.32. Unpaired t-test was used to
compare the mean values of the EpiMatrix Z-scores per HLA
allele for each 9-mer in the Malawi CSP variants dataset and the
set of random proteins. Differences were considered significant
for p < 0.05. Also, The D’Agostino-Pearson normality test was
used to check for normality of distribution within the datasets. In
addition, Pearson correlation analyses were performed to estab-
lish the relationship between the JanusHuman scores and the
JanusMalaria scores as well as the relationship between
JanusHuman scores and ClustiMer scores. Pearson correlation
was also applied to evaluate the relationship between EpiCC
scores and Janus homology scores.
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